On Monday, Tarsus Pharmaceuticals Inc (NASDAQ: TARS) opened higher 4.78% from the last session, before settling in for the closing price of $49.97. Price fluctuations for TARS have ranged from $20.08 to $57.28 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 172.29%. Company’s average yearly earnings per share was noted 42.49% at the time writing. With a float of $35.81 million, this company’s outstanding shares have now reached $38.35 million.
Let’s determine the extent of company efficiency that accounts for 323 employees. In terms of profitability, gross margin is 92.99%, operating margin of -65.9%, and the pretax margin is -63.16%.
Tarsus Pharmaceuticals Inc (TARS) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Tarsus Pharmaceuticals Inc is 13.94%, while institutional ownership is 94.59%. The most recent insider transaction that took place on Mar 24 ’25, was worth 300,000. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Commercial Officer sold 3,643 for $46.29, making the entire transaction worth $168,634. This insider now owns 71,979 shares in total.
Tarsus Pharmaceuticals Inc (TARS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 42.49% per share during the next fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
Check out the current performance indicators for Tarsus Pharmaceuticals Inc (TARS). In the past quarter, the stock posted a quick ratio of 4.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.81 in the next quarter and is forecasted to reach 1.10 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Looking closely at Tarsus Pharmaceuticals Inc (NASDAQ: TARS), its last 5-days average volume was 0.78 million, which is a jump from its year-to-date volume of 0.66 million. As of the previous 9 days, the stock’s Stochastic %D was 88.43%. Additionally, its Average True Range was 2.83.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 73.23%, which indicates a significant decrease from 97.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.00% in the past 14 days, which was higher than the 53.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $48.65, while its 200-day Moving Average is $39.57. However, in the short run, Tarsus Pharmaceuticals Inc’s stock first resistance to watch stands at $53.86. Second resistance stands at $55.36. The third major resistance level sits at $58.09. If the price goes on to break the first support level at $49.63, it is likely to go to the next support level at $46.90. Should the price break the second support level, the third support level stands at $45.40.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
There are currently 38,377K shares outstanding in the company with a market cap of 2.18 billion. Presently, the company’s annual sales total 182,950 K according to its annual income of -115,550 K. Last quarter, the company’s sales amounted to 66,410 K and its income totaled -23,110 K.
